Sickle cell disease and stroke

Blood

Volumn 114, Issue 25, 2009, Pages 5117-5125

  Verduzco, Luis A ^a   Nathan, David G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; ANTIINFLAMMATORY AGENT; ANTISICKLING AGENT;

ALLOIMMUNIZATION; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; BLOOD VISCOSITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; HEMATOCRIT; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; IRON OVERLOAD; OXYGEN TRANSPORT; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SICKLE CELL ANEMIA; STROKE; THALASSEMIA; BONE MARROW TRANSPLANTATION; DRUG THERAPY; PHLEBOTOMY;

ANEMIA, SICKLE CELL; ANTI-INFLAMMATORY AGENTS; ANTISICKLING AGENTS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; DRUG THERAPY; HUMANS; HYDROXYUREA; PHLEBOTOMY; STROKE;

EID: 73949087363     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-220921     Document Type: Review

References (114)

1. Gavins F, Yilmaz G, Granger DN. The evolving paradigm for blood cell-endothelial cell interactions in the cerebral microcirculation. Microcirculation. 2007;14(7):667-681.
2. Boyton R. The role of natural killer T cells in lung inflammation. J Pathol. 2008;214(2):276-282.
3. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106(3):337-338.
4. Platt OS. Preventing stroke in sickle cell anemia. N Engl J Med. 2005;353(26):2743-2745.
5. Sydenstricked VP, Mulherin WA, Houseal RW. The AJDC archives. August 1923. Sickle cell anemia. Report of two cases in children, with necropsy in one case. By V. P. Sydenstricked [sic], W. A. Mulherin and R. W. Houseal. Am J Dis Child. 1987;141(6):612-615.
6. Savitt TL, Goldberg MF. Herrick's 1910 case report of sickle cell anemia: the rest of the story. JAMA. 1989;261(2):266-271.
7. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972;287(17):846-849.
8. Cushman M, Cantrell RA, McClure LA, et al. Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol. 2008;64(5):507-513.
9. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1): 288-294.
10. Broderick J, Talbot GT, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. J Child Neurol. 1993;8(3):250-255.
11. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42(5):699-704.
12. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol. 1996;17(5):965-972.
13. Pavlakis SG, Bello J, Prohovnik I, et al. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol. 1988;23(2):125-130.
14. Armstrong FD, Thompson RJ Jr, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease: Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996; 97(6):864-870.
15. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999;103(3):640-645.
16. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993; 81(5):1109-1123.
17. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461-471.
18. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896-899.
19. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;63(1):162-169.
20. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778.
21. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118(3): 377-382.
22. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94(9):3022-3026.
23. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-352.
24. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
25. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104(2):336-339.
26. Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer. 2008;51(5):647-651.
27. Olivieri NF, Brittenham GM, Matsui D, et al. Ironchelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med. 1995; 332(14):918-922.
28. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-252.
29. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of ironchelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339(7):417-423.
30. Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol. 1986;8(2):436-440.
31. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-1929.
32. Kwiatkowski JL, Cohen AR. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin North Am. 2004;18(6):1355-1377.
33. Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion. 2007; 47(10):1820-1829.
34. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label phase II trial. Acta Haematol. 2008;119(3):133-141.
35. Seibert JJ, Glasier CM, Kirby RS, et al. Transcranial Doppler, MRA, and MRI as a screening examination for cerebrovascular disease in patients with sickle cell anemia: an 8-year study. Pediatr Radiol. 1998;28(3):138-142.
36. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-1322.
37. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550-1554.
38. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7):2685-2690.
39. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-1047.
40. Tavakkoli F, Nahavandi M, Wyche MQ, Castro O. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study. Clin Ther. 2005;27(7): 1083-1088.
41. Frenette PS. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation. 2004;11(2):167-177.
42. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood. 2008;111(11):5271-5281.
43. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362-1369.
44. Fruchtman SMKM, Peterson P, Mack K, Berk PD, Wasserman LF. Acute leukemia, hydroxyurea and polycythemia vera: an analysis of risk from the polycythemia vera study group. Blood. 1994;84: A518.
45. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52(3):134-139.
46. Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol. 1994;36(5):367-372.
47. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease: Cooperative Study of Sickle Cell Disease. Blood. 1995;86(2):776-783.
48. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang. 1990; 58(1):50-55.
49. Sirchia G, Zanella A, Parravicini A, Morelati F, Rebulla P, Masera G. Red cell alloantibodies in thalassemia major: results of an Italian cooperative study. Transfusion. 1985;25(2):110-112.
50. Coles SM, Klein HG, Holland PV. Alloimmunization in two multitransfused patient populations. Transfusion. 1981;21(4):462-466.
51. Economidou J, Constantoulakis M, Augoustaki O, Adinolfi M. Frequency of antibodies to various antigenic determinants in polytransfused patients with homozygous thalassaemia in Greece. Vox Sang. 1971;20(3):252-258.
52. National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources. The Management of Sickle Cell Disease, 4th ed. Bethesda, MD: National Institutes of Health; 2002.
53. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med. 2005;129(2):190-193.
54. Afenyi-Annan A, Willis MS, Konrad TR, Lottenberg R. Blood bank management of sickle cell patients at comprehensive sickle cell centers. Transfusion. 2007;47(11):2089-2097.
55. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease: the Cooperative Study of Sickle Cell Disease. Blood. 1990;76(7):1431-1437.
56. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. Red cell alloimmunization in sickle cell disease. Br J Haematol. 1986;63(2):241-245.
57. Orlina AR, Unger PJ, Koshy M. Posttransfusion alloimmunization in patients with sickle cell disease. Am J Hematol. 1978;5(2):101-106.
58. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion. 2002;42(6):684-690.
59. Price CL, Boyd JH, Watkins AR, Fleming F, DeBaun MR. Mailing of a sickle cell disease educational packet increases blood donors within an African American community. Transfusion. 2006; 46(8):1388-1393.
60. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a strokeprevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41(9):1086-1092.
61. Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol. 1999;104(1): 189-194.
62. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L, Pelegrinis E, Karaklis A. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang. 1987;52(1): 95-98.
63. Flickinger C. In search of red blood cells for alloimmunized patients with sickle cell disease. Immunohematology. 2006;22(3):136-142.
64. Velilla PA, Rugeles MT, Chougnet CA. Defective antigen-presenting cell function in human neonates. Clin Immunol. 2006;121(3):251-259.
65. Hodge S, Hodge G, Flower R, Han P. Cord blood leucocyte expression of functionally significant molecules involved in the regulation of cellular immunity. Scand J Immunol. 2001;53(1):72-78.
66. Upham JW, Lee PT, Holt BJ, et al. Development of interleukin-12-producing capacity throughout childhood. Infect Immun. 2002;70(12):6583-6588.
67. Chelvarajan RL, Collins SM, Doubinskaia IE, et al. Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens. J Leukoc Biol. 2004; 75(6):982-994.
68. Han P, McDonald T, Hodge G. Potential immaturity of the T-cell and antigen-presenting cell interaction in cord blood with particular emphasis on the CD40-CD40 ligand costimulatory pathway. Immunology. 2004;113(1):26-34.
69. Takahata Y, Nomura A, Takada H, et al. CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. Exp Hematol. 2004;32(7):622-629.
70. Clerici M, DePalma L, Roilides E, Baker R, Shearer GM. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest. 1993;91(6):2829-2836.
71. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42(1):37-43.
72. Cobb LA, Kramer RJ, Finch CA. Circulatory effects of chronic hypervolemia in polycythemia vera. J Clin Invest. 1960;39:1722-1728.
73. Richardson T, Guyton A. Effects of polycythemia and anemia on cardiac output and other circulatory factors. Am J Physiol. 1959;197:1167-1170.
74. Fahraeus R, Lindquvist T. The viscosity of the blood in narrow capillary tubes. Am J Physiol. 1931;96:562-568.
75. Levy MN, Share L. The influence of erythrocyte concentration upon the pressure-flow relationships in the dog's hind limb. Circ Res. 1953;1(3): 247-255.
76. Whittaker SR, Winton FR. The apparent viscosity of blood flowing in the isolated hindlimb of the dog, and its variation with corpuscular concentration. J Physiol. 1933;78(4):339-369.
77. Nakamura T, Hasegawa S, Shio H, Uyesaka N. Rheologic and pathophysiologic significance of red cell passage through narrow pores. Blood Cells. 1994;20(1):151-165; discussion 166-168.
78. Lumsden JH, Mullen K, McSherry BJ. Canine hematology and biochemistry reference values. Can J Comp Med. 1979;43(2):125-131.
79. Mohandas N, Clark MR, Jacobs MS, Shohet SB. Analysis of factors regulating erythrocyte deformability. J Clin Invest. 1980;66(3):563-573.
80. Baskurt OK. Deformability of red blood cells from different species studied by resistive pulse shape analysis technique. Biorheology. 1996;33(2):169-179.
81. Embury SH, Backer K, Glader BE. Monovalent cation changes in sickle erythrocytes: a direct reflection of alpha-globin gene number. J Lab Clin Med. 1985;106(1):75-79.
82. Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood. 1986;68(5):985-990.
83. Billett HH, Nagel RL, Fabry ME. Paradoxical increase of painful crises in sickle cell patients with alpha-thalassemia. Blood. 1995;86(11):4382.
84. Patel VP, Ciechanover A, Platt O, Lodish HF. Mammalian reticulocytes lose adhesion to fibronectin during maturation to erythrocytes. Proc Natl Acad Sci U S A. 1985;82(2):440-444.
85. Higgins JM, Eddington DT, Bhatia SN, Mahadevan L. Sickle cell vasoocclusion and rescue in a microfluidic device. Proc Natl Acad Sci U S A. 2007;104(51):20496-20500.
86. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol. 1986;20(6): 684-690.
87. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke. 1978;9(1):45-52.
88. Koshy M, Thomas C, Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys. 1990;1(3):71-78.
89. Wallace KL, Marshall MA, Ramos SI, et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-γ and CXCR3 chemokines. Blood. 2009;114(3):667-676.
90. Schmalzer EA, Lee JO, Brown AK, Usami S, Chien S. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels: implications for transfusion. Transfusion. 1987;27(3): 228-233.
91. Alexy T, Pais E, Armstrong JK, Meiselman HJ, Johnson CS, Fisher TC. Rheologic behavior of sickle and normal red blood cell mixtures in sickle plasma: implications for transfusion therapy. Transfusion. 2006;46(6):912-918.
92. Sebastiani P, Nolan VG, Baldwin CT, et al. A network model to predict the risk of death in sickle cell disease. Blood. 2007;110(7):2727-2735.
93. Hoppe C, Cheng S, Grow M, et al. A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. Br J Haematol. 2001;114(3):718-720.
94. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197-1199.
95. Uda M, Galanello R, Sanna S, et al. Genomewide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105(5):1620-1625.
96. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105(33):11869-11874.
97. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842.
98. Sankaran VG. Developmental and speciesdivergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093-1097.
99. Khan MA, Gallo RM, Renukaradhya GJ, Du W, Gervay-Hague J, Brutkiewicz RR. Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation. J Immunol. 2009;182(8): 4744-4750.
100. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
101. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3):840-846.
102. Sevigny CP, Li L, Awad AS, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol. 2007;178(7):4240-4249.
103. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol. 2005;175(7):4383-4391.
104. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203(12):2639-2648.
105. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14(7):1315-1323.
106. Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol. 2003;65(4):493-501.
107. Kaneko S, Okumura K, Numaguchi Y, et al. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sci. 2000;67(2):101-112.
108. Walters MC, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996;2(2): 100-104.
109. Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14(11):1270-1278.
110. Woodard P, Helton KJ, Khan RB, et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol. 2005;129(4):550-552.
111. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for children with sickle cell disease. Cochrane Database Syst Rev. 2009;(1):CD007001.
112. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335(6):369-376.
113. Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42(8): 523-527.
114. Whte DA, Moinuddin A, McKinstry RC, Noetzel M, Armstrong M, DeBaun M. Cognitive screening for silent cerebral infarction in children with sickle cell disease. J Pediatr Hematol Oncol. 2006; 28(3):166-169.